A U.S. study suggests that the effectiveness of biotech drugs derived from animals might be reduced by Neu5Gc, a nonhuman sialic acid, and the problem could "exacerbate a chronic inflammation process" in some people. Neu5Gc contamination is unavoidable in animal-based treatments, but its effect might be contained by adding the human sugar Neu5Ac to the manufacturing process, researchers reported.

Related Summaries